Eli Lilly (LLY) PT Raised to $853 at Jefferies

Jefferies analyst Akash Tewari raised the price target on Eli Lilly (NYSE: LLY) to $853.00 (from $814.00) while maintaining a Buy rating.

The analyst commented: "We've gotten Q's on orfo safety & DDI. Overall we're optimistic #1. Our analysis suggests orfo's DDI profile could be manageable (LLY has run & completed a # of DDI studies w/ CYP/P-gp substrates) & we don't expect it to be sig. different vs danu, which is a weak CYP3A4/5 inhibitor, #2. We're comfortable w/ orfo's liver tox profile (transient enzyme incr.) & believe AZN licensing ECC5004 could be de-risking. We model ~$14B risk-adj PS for orfo vs $11B cons."

You May Also Be Interested In

• Teva Pharma (TEVA) PT Raised to $52 at Oppenheimer
• Community Healthcare Trust (CHCT) PT Lowered to $17 at Truist Securities
• Amrize Ltd (AMRZ) PT Lowered to $32 at RBC Capital